A Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV

被引：30

作者：

Tabaja, Hussam ^{[1
]}

Kanj, Amjad ^{[2
]}

El Zein, Said ^{[1
]}

Comba, Isin Yagmur ^{[1
]}

Chehab, Omar ^{[3
]}

Mahmood, Maryam ^{[1
]}

机构：

[1] Mayo Clin, Div Infect Dis, Rochester, MN 55905 USA

[2] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA

[3] Johns Hopkins Univ, Div Internal Med, Baltimore, MD USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2022年 / 9卷 / 04期

关键词：

AIDS; hemophagocytosis; HIV; lymphohistiocytosis; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; DISSEMINATED HISTOPLASMOSIS; AIDS PATIENT; INFECTION; DIAGNOSIS; LYMPHOMA; CYTOMEGALOVIRUS; GUIDELINES; SECONDARY; SARCOMA;

D O I：

10.1093/ofid/ofac071

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We provide an elaborate review of cases published between January 2005 and April 2021 on hemophagocytic lymphohistiocytosis (HLH) in HIV patients. Seventy articles describing 81 adult patients (age >= 19 years) were included. The median age was 40 years, and 78% were males. Only 65% were known to have HIV before presentation. CD4 count was >= 200 cells/mm(3) in 23%, and HIV viral load was <200 copies/mL in 41%. The lack of meticulous reporting of >= 5 of 8 criteria for HLH diagnosis was evident in a third of cases. At least 1 infectious agent-other than HIV-was believed to trigger HLH in 78% of patients. The most common were Epstein-Barr virus (26%), human herpesvirus 8 (21%), and Histoplasma capsulatum (17%). Sixty percent survived. Among those, 93% received treatment for identified secondary trigger(s), while 51% received HLH-directed therapy. There was significant heterogeneity in the treatment regimens used for HLH.

引用

页数：10

共 87 条

[1] Hemophagocytic Syndrome in an Acute Human Immunodeficiency Virus Infection [J].